Dermatology · Investigational
SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate)
No lawful US pathway
01 · Overview
SYN-AKE is a synthetic dipeptide derivative modeled on waglerin-1, a peptide from Temple viper venom that blocks the adult muscle-type nicotinic acetylcholine receptor (PMID 10087048). The manufacturer describes SYN-AKE as a reversible antagonist of muscle nicotinic receptors that relaxes facial muscles and smooths expression lines, but this receptor activity has not been confirmed in independent peer-reviewed studies.
It is marketed as a topical alternative to botulinum toxin.
02 · Research summary & key findings
Independent laboratory research is limited; one study using computer docking and cell assays reported antioxidant activity and no cytotoxicity or mutagenicity, and predicted binding to skin-aging enzymes, but did not test nicotinic receptor blockade (PMID 37349941). The only clinical data found involve a multi-ingredient serum containing SYN-AKE, acetyl hexapeptide-8, gluconolactone, and niacinamide, which improved static and dynamic wrinkle scores over 12 weeks in two uncontrolled studies of 50 and 42 participants (PMID 41668671); the contribution of SYN-AKE itself cannot be isolated. No placebo-controlled trials of SYN-AKE alone have been published.
03 · Regulatory status
SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 1 FDA-approved compound in Dermatology
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for longevity and healthy ageing?
SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on longevity and healthy ageing, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Topical
References
- [1]Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor J Pharmacol Exp Ther, 1999. PMID 10087048
- [2]Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests J Biomol Struct Dyn, 2024. PMID 37349941
- [3]The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies Int J Cosmet Sci, 2026. PMID 41668671
Primary literature
- PubMed: "SYN-AKE"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "SYN-AKE"
Registered interventional and observational studies, including status and phase.
- PubChem: "SYN-AKE"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Dermatology
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.